Amgen Inc. Deferred Tax Liabilities, Gross
Amgen Inc. (AMGN) had Deferred Tax Liabilities, Gross of $3.24 billion as of 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net
us-gaap:DeferredIncomeTaxLiabilities · last filed 2026-02-13
- 2025-12-31: Deferred Tax Liabilities, Gross $3.24B.
- 2024-12-31: Deferred Tax Liabilities, Gross $3.34B.
- 2023-12-31: Deferred Tax Liabilities, Gross $4.11B.
- 2022-12-31: Deferred Tax Liabilities, Gross $1.88B.
| Period end | Deferred Tax Liabilities, Gross |
|---|---|
| 2025-12-31 | $3.24B 10-K · filed 2026-02-13 |
| 2024-12-31 | $3.34B 10-K · filed 2026-02-13 |
| 2023-12-31 | $4.11B 10-K · filed 2025-02-14 |
| 2022-12-31 | $1.88B 10-K · filed 2024-02-14 |
| 2021-12-31 | $1.45B 10-K · filed 2023-02-09 |
| 2020-12-31 | $1.52B 10-K · filed 2022-02-16 |
| 2019-12-31 | $1.78B 10-K · filed 2021-02-09 |
| 2018-12-31 | $1.96B 10-K · filed 2020-02-12 |
| 2017-12-31 | $2.17B 10-K · filed 2019-02-13 |
| 2016-12-31 | $3.79B 10-K · filed 2018-02-13 |
| 2015-12-31 | $3.86B 10-K · filed 2017-02-14 |
| 2014-12-31 | $4.32B 8-K · filed 2016-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |